Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2Rγnull mice engrafted with mobilized human hemopoietic stem cells

…, X Chen, S Chaleff, M Kotb, SD Gillies… - The Journal of …, 2005 - journals.aai.org
Ethical considerations constrain the in vivo study of human hemopoietic stem cells (HSC). To
overcome this limitation, small animal models of human HSC engraftment have been used. …

A tissue-specific transcription enhancer element is located in the major intron of a rearranged immunoglobulin heavy chain gene

SD Gillies, SL Morrison, VT Oi, S Tonegawa - Cell, 1983 - cell.com
We have studied the DNA sequences required for high level expression of a cloned heavy
chain immunoglobulin gene stably introduced into mouse myeloma cells by DNA transfection. …

Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis

…, E Sylvin, KM Lo, S Gillies… - Proceedings of the …, 2003 - National Acad Sciences
Plaque angiogenesis promotes the growth of atheromas, but the functions of plaque
capillaries are not fully determined. Neovascularization may act as a conduit for the entry of …

Structure, organization, and somatic rearrangement of T cell gamma genes

AC Hayday, H Saito, SD Gillies, DM Kranz, G Tanigawa… - Cell, 1985 - cell.com
We present the initial characterization of a novel family of genes that rearrange in T cells, but
do not encode either of the defined (o//3) subunits of the clonespecific heterodimer of the T …

High-level expression of chimeric antibodies using adapted cDNA variable region cassettes

SD Gillies, KM Lo, J Wesolowski - Journal of immunological methods, 1989 - Elsevier
A rapid and generally applicable method for the modification of immunoglobulin cDNAs was
developed so that the variable (V) regions could be expressed as cassettes, together with a …

Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells.

SD Gillies, EB Reilly, KM Lo… - Proceedings of the …, 1992 - National Acad Sciences
A genetically engineered fusion protein consisting of a chimeric anti-ganglioside GD2
antibody (ch14.18) and interleukin 2 (IL2) was tested for its ability to enhance the killing of …

[HTML][HTML] Antitumor activity of hu14. 18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study

S Shusterman, WB London, SD Gillies… - Journal of Clinical …, 2010 - ncbi.nlm.nih.gov
Purpose The hu14. 18-IL2 fusion protein consists of interleukin-2 molecularly linked to a
humanized monoclonal antibody that recognizes the GD2 disialoganglioside expressed on …

Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody.

BM Mueller, CA Romerdahl, SD Gillies… - Journal of immunology …, 1990 - journals.aai.org
A mouse/human chimeric antibody (ch14.18) was developed that reacts with the
disialoganglioside GD2 on the surface of tumor cells of neuroectodermal origin. ch14.18 has the …

NK cells engineered to express a GD2‐specific antigen receptor display built‐in ADCC‐like activity against tumour cells of neuroectodermal origin

…, D Stefes, S Kloess, D Seidel, SD Gillies… - Journal of cellular …, 2012 - Wiley Online Library
Abstract Treatment of high‐risk neuroblastoma (NB) represents a major challenge in
paediatric oncology. Alternative therapeutic strategies include antibodies targeting the …

Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow

…, RA Reisfeld, NM Varki, SD Gillies - Journal of the …, 1997 - academic.oup.com
Background: Advanced (stage 4) cases of neuroblastoma, a childhood cancer of the
nervous system, are associated with high relapse rates, even after intensive chemotherapy, …